Effect of Low-Dose, Long-Term Roxithromycin on Airway Inflammation and Remodeling of Stable Noncystic Fibrosis Bronchiectasis

Figure 3

Variation of IL-8, NE, MMP-9, TIMP-1, MMP9/TIMP-1, HA, and type IV collagen in induced sputum from baseline to 6 months in both groups. (a) There was no statistical difference in IL-8 from baseline to 6 months in controls; (b) effect of roxithromycin on induced sputum IL-8 concentration (μg/L) in patients with NCFB from baseline to 6 months of treatment (); (c) induced sputum NE concentration (ng/mL) in patients with NCFB increasing from baseline to 6 months in controls (); (d) effect of roxithromycin on induced sputum NE concentration (ng/mL) in patients with NCFB from baseline to 6 months of treatment (); (e) induced sputum MMP-9 concentration (μg/L) in patients with NCFB increasing from baseline to 6 months in controls (.011); (f) effect of roxithromycin on induced sputum MMP-9 concentration (μg/L) in patients with NCFB from baseline to 6 months of treatment (); (g) there was no statistical difference in TIMP-1 from baseline to 6 months in controls; (h) there was no statistical difference in TIMP-1 from baseline to 6 months in roxithromycin; (i) there was no statistical difference in MMP9/TIMP-1 from baseline to 6 months in controls; (j) effect of roxithromycin on induced sputum MMP9/TIMP-1 in patients with NCFB from baseline to 6 months of treatment (); (k) induced sputum HA concentration (ng/mL) in patients with NCFB increased from baseline to 6 months in controls (); (l) effect of roxithromycin on induced sputum hyaluronidase concentration (ng/mL) in patients with NCFB from baseline to 6 months of treatment (); (m) there was no statistical difference in sputum type IV collagen concentration from baseline to 6 months in controls; (n) effect of roxithromycin on induced sputum type IV collagen concentration (μg/L) in patients with NCFB from baseline to 6 months of treatment ().

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)